One of Merck KGaA’s leading immunology assets has flunked the latest part of a phase 2 lupus trial. Despite the primary endpoint miss, Merck has concluded further development is warranted in ...

Merck licenses the protein, called berahyaluronidase alfa, from Alteogen. Merck has filed a petition with the U.S. Patent and Trademark Office to challenge seven of Halozyme’s patents.

Both Merck & Co. and Halozyme are holding their ground in a freshly unveiled patent dispute surrounding the New Jersey pharma’s under-the-skin version of its blockbuster cancer drug Keytruda.

The drugmaker Merck announced it has opened a $1 billion vaccine manufacturing facility in north Durham, a 225,000-square-foot addition to the company’s existing campus off Old Oxford Road.

40% of Merck & Co., Inc.'s revenues are driven by cancer med Keytruda, which faces patent expiry by 2028, posing a significant risk to future earnings and share price value. The company is ...

Merck's stock trades at a low valuation as investors worry about Keytruda's looming patent cliff. The company is looking to a new, subcutaneous formulation, which could help sales remain strong ...

Moderna (NASDAQ:MRNA) is targeting market approval of a personalized vaccine the company is developing with Merck (NYSE:MRK) for skin cancer in 2027, one of its top executives announced at an ...

Opening highlights effort to expand U.S. manufacturing through a $1 billion investment DURHAM, N.C., March 11, 2025--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States ...

Biotech Halozyme Therapeutics believes the new version of Merck's blockbuster cancer drug Keytruda infringes on its patents, the Wall Street Journal reported on Wednesday (March 5, 2025), citing ...

March 11 (Reuters) - Merck (MRK.N), opens new tab said on Tuesday it has opened a $1-billion facility at its North Carolina site, the latest drugmaker to boost its U.S. manufacturing amid ...

STORY HIGHLIGHTS Merck opens new vaccine facility in Durham. New facility will manufacture HPV vaccines Gardasil and Gardasil 9. Merck plans to invest $8 billion more in U.S. by 2028. A global ...